In a report issued on May 6, Brian Skorney from Robert W. Baird maintained a Hold rating on Regeneron (REGN – Research Report), with a price target of $570.00. The company’s shares closed last Friday at $496.75.
According to TipRanks.com, Skorney is a 3-star analyst with an average return of 4.5% and a 49.4% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $649.70, representing a 30.6% upside. In a report issued on May 6, Raymond James also assigned a Hold rating to the stock.
Regeneron’s market cap is currently $52.92B and has a P/E ratio of 16.20. The company has a Price to Book ratio of 4.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.